ipscell.com
Interview with Jane Lebkowski on Asterias FDA-approved Stem Cell Trial - The Niche
The BioTime subsidiary, Asterias, has received FDA approval for a combined Phase I/IIa clinical trial of OPC1 for treating spinal cord injury. BioTime (BTX) and Asterias (ASTY) have picked up the portfolio of the former Geron clinical trial using oligodendrocyte precursor cells (OPC). Asterias also acquired a second element from Geron in the form of a lung … Interview with Jane Lebkowski on Asterias FDA-approved Stem Cell Trial Read More »
Professor Paul Knoepfler, Ph.D.